Investor Call Details?, page-19

Well, bugger, I just posted a lengthy (for me) comment and nothing showed on HC...must have pushed a wrong button. So I'll try again in more abbreviated form.

I appreciated the recorded message from BB.It gave more info and intuition that written ones to date.
He clearly was expecting retail shareholders to grill him (presumably aware of comments on HC and to the PR contractor), and is probably thinking we are just keyboard warriors. If future quarterly reviews get no retail feedback as well, he's entitled to insulate himself from negative chatter.

My excuse is that it was perfect weather for a burnoff and with the fire well underway, I was tied up!

The one thing I was going to quiz him on was the extent to which current approvals open up the market. He touched on it, but in a way which I felt was misleading by what he didnt say, rather than by what he did say.If you listen carefully, when talking about what tests to target next he said clearly current approval is urine on agar media. I suspect most would have missed the limitation ...he did not say approved for urine tests. My understanding is that the FDA approval needs updating for each media and labs standardise on one media only. ie While presumably agar is the most common, other customers not using that are not a viable market segment currently. With FDA approval being simpler for modifying an approved test for different media, than for a completely new test, I'd have thought they would be persued early on, and approvals announced. No announcement and BB saying urine on agar comfirms to me that limitation currently.